文献速递白血病淋巴瘤

慢性淋巴细胞白血病患者降低伊布替尼剂量的初步研究

A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
PubMed 文献 · Blood · 2018-09-25

这项初步研究(NCT02801578)在11例慢性淋巴细胞白血病患者中,于首个28天周期使用伊布替尼420 mg/d后,第2周期降至280 mg/d、第3周期降至140 mg/d,比较不同剂量的药代动力学、BTK占有率和药效动力学反应。结果显示血浆和细胞内伊布替尼水平呈剂量依赖性,最低剂量平均仍可占据超过95%的BTK蛋白,下游信号抑制和CCL3、CCL4下降在三周期相似。作者认为标准剂量1周期后降低剂量不丧失生物活性,但低剂量的临床疗效需系统评估。

要点

  • 11例患者开始治疗,9例完成3个28天周期。
  • 伊布替尼血浆和细胞内水平呈剂量依赖性,140 mg/d平均仍占据超过95%的BTK蛋白。
  • 140 mg/d时BTK下游信号抑制维持,CCL3和CCL4下降在三周期相似。

核心结论

  • 药代动力学/药效动力学数据表明,标准420 mg/d伊布替尼治疗1个周期后降低剂量不丧失生物活性。
  • 低剂量的临床疗效需要系统评估。

研究设计与样本

  • 初步研究(NCT02801578),在慢性淋巴细胞白血病患者同一患者内于三个28天周期中系统降低伊布替尼剂量。
  • 首个周期420 mg/d,第2周期降至280 mg/d,第3周期降至140 mg/d。
  • 11例患者开始研究治疗,9例完成3个周期。

主要发现

  • 伊布替尼血浆和细胞内水平呈剂量依赖性,最低剂量平均仍占据超过95%的BTK蛋白。
  • 第3周期140 mg/d时BTK下游信号抑制维持,总BTK和磷酸化BTK(Tyr223)蛋白水平在三周期下降程度相当。
  • 血浆趋化因子CCL3和CCL4水平下降在三周期相似。

临床怎么用

  • 作者认为,标准420 mg/d伊布替尼治疗1个周期后降低剂量不丧失生物活性。
  • 作者指出低剂量的临床疗效需要系统评估。
  • 作者认为降低剂量可降低药物费用、减少不良反应并促进基于机制的联合治疗。

局限性

  • 低剂量的临床疗效需要系统评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ibrutinib is highly efficacious and used at 420 mg/d for treatment of chronic lymphocytic leukemia (CLL). We previously demonstrated a decline in Bruton's tyrosine kinase (BTK) protein levels in CLL cells after 1 cycle of ibrutinib, suggesting ibrutinib dose could be lowered after the first cycle without loss of biological effect. To test this postulate, a pilot study (NCT02801578) was designed to systematically reduce ibrutinib dosing within the same patient with CLL over the course of three 28-day cycles. After an initial cycle of 420 mg/d, the dose was reduced to 280 mg/d in cycle 2, and then to 140 mg/d in cycle 3. Eleven patients began study treatment, and 9 completed the 3 cycles. Plasma and intracellular pharmacokinetics (PK), BTK occupancy, and pharmacodynamic (PD) response at different doses of ibrutinib were compared. Plasma and intracellular levels of ibrutinib were dose-dependent, and even the lowest dose was sufficient to occupy, on average, more than 95% of BTK protein. In concert, BTK downstream signaling inhibition was maintained with 140 mg/d ibrutinib in cycle 3, and there were comparable reductions in total and phospho-BTK (Tyr223) protein levels across 3 cycles. Reductions of plasma chemokine CCL3 and CCL4 levels, considered to be biomarkers of ibrutinib response, were similar during the 3 cycles. These PK/PD data demonstrate that after 1 cycle of ibrutinib at the standard 420 mg/d dose, the dose can be reduced without losing biological activity. Clinical efficacy of lower doses needs to be systematically evaluated. Such dose reductions would lower drug cost, lessen untoward toxicity, and facilitate rationale-based combinations. This trial was registered at www.clinicaltrials.gov as #NCT02801578.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chen LS, Bose P, Cruz ND, et al. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018. PMID: 30254130. doi:10.1182/blood-2018-06-860593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。